{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05159700",
            "orgStudyIdInfo": {
                "id": "PRJ1-3024 CS101"
            },
            "organization": {
                "fullName": "Zhuhai Yufan Biotechnologies Co., Ltd",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors",
            "officialTitle": "A Phase I, First-In-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-phase-i-study-evaluating-the-safety-pharmacokinetics-and-efficacy-of-in-subjects-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-02-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-12-07",
            "studyFirstSubmitQcDate": "2021-12-15",
            "studyFirstPostDateStruct": {
                "date": "2021-12-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Zhuhai Yufan Biotechnologies Co., Ltd",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.",
            "detailedDescription": "The study will evaluate the safety, tolerability, PK, and pharmacodynamics of PRJ1-3024 and will determine the maximum tolerated dose in subjects with advanced solid tumors.\n\nPRJ1-3024 will be evaluated as an oral therapeutic that tests the anti-tumor activity of PRJ1-3024 in patients with solid tumors and has not yet been tested in humans.\n\nThis study will find the safe and tolerable recommended dose in subjects with advanced solid tumors as a open-label, 3+3 dose escalation study."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Advanced Solid Malignancies"
            ],
            "keywords": [
                "First in human",
                "Maximum tolerated dose",
                "Recommended Phase 2 dose",
                "Dose Escalation",
                "Hematopoietic progenitor kinase 1",
                "PRJ1-3024"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "This is a Phase 1, open label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 46,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.",
                    "interventionNames": [
                        "Drug: PRJ1-3024"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PRJ1-3024",
                    "description": "PRJ1-3024 is provided as capsules and is administered orally once a day.",
                    "armGroupLabels": [
                        "Monotherapy Escalation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of dose-limiting toxicity (DLT) events during the DLT monitoring period",
                    "description": "Safety listings and pharmacokinetic listings will be used for evaluation",
                    "timeFrame": "Day 1 to Day 21"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs)",
                    "description": "Characterized by type, seriousness, relationship to study treatment, timing, and severity.",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Pharmacokinetic parameter\uff1a Accumulation ratio",
                    "description": "to estimate the accumulation of PRJ1-3024 from time 0 to the time of last quantifiable concentration after multiple administration",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Objective response rate (ORR)",
                    "description": "estimated by the proportion of subjects having a complete response (CR) or partial response (PR) with use of RECIST v1.1 criteria.",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "defined as time from the first occurrence of a documented objective response to the time of relapse or death from any cause.",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Pharmacokinetic parameter\uff1aAUC\uff080-last\uff09",
                    "description": "Area under the concentration-time curve AUC from time 0 to the time of the last quantifiable concentration",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Pharmacokinetic parameter\uff1aMaximum observed concentration (Cmax)",
                    "description": "assessed as time from time 0 to the time of the last quantifiable concentration",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced (unresectable) or metastatic r/r solid tumors for which no standard therapy is available or for whom standard therapy is considered unsuitable or intolerable.\n* Male or non-pregnant, non-lactating female subjects age \u226518 years.\n* ECOG Performance Status 0\\~2.\n* Has at least 1 measurable lesion as defined by RECIST 1.1 criteria .\n* Life expectancy of \\>3 months, in the opinion of the Investigator.\n* Able to take oral medications and willing to record daily adherence to investigational product.\n* Adequate hematologic parameters unless clearly due to the disease under study.\n* Adequate renal and hepatic function\n* Able to understand and willing to sign a written informed consent form.\n\nKey Exclusion Criteria:\n\n* History of another malignancy\n* Known symptomatic brain metastases requiring \\>10 mg/day of prednisolone.\n* Significant cardiovascular disease\n* Known active HBV, HCV, AIDS-related illness.\n* Has received a live vaccine within 30 days\n* History of active autoimmune disorders or ongoing immunosuppressive therapy.\n* Receiving concurrent anti-cancer therapy, investigational product, strong inhibitors or inducers of cytochrome P450 3A (CYP3A) .\n* Prior treatment with hematopoietic progenitor kinase 1 (HPK1) inhibitors.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Yang Xu",
                    "role": "CONTACT",
                    "phone": "8054905672",
                    "email": "yang.xu@ming-med.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Yang Xu, PhD",
                    "affiliation": "Head of US Clinical Development",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sarah Cannon Research Institute at HealthONE",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jason Henry, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute at Florida Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32827",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cesar Perez, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Christ Hospital",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "21073",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Starodub, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "73301",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Vandross, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Mays Cancer Center",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Daruka Mahadevan, MD, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Spira, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}